Publications
Detailed Information
Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805) : x
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Kihyun | - |
dc.contributor.author | Kim, Jin Seok | - |
dc.contributor.author | Yoon, Sung-Soo | - |
dc.contributor.author | Yoon, Dok Hyun | - |
dc.contributor.author | Eom, Hyeon-Seok | - |
dc.contributor.author | Lee, Je-Jung | - |
dc.contributor.author | Yim, Hyeon Woo | - |
dc.contributor.author | Park, Misun | - |
dc.contributor.author | Lee, Hojoon | - |
dc.contributor.author | Min, Chang-Ki | - |
dc.date.accessioned | 2022-09-29T03:18:07Z | - |
dc.date.available | 2022-09-29T03:18:07Z | - |
dc.date.created | 2022-07-11 | - |
dc.date.issued | 2022-07 | - |
dc.identifier.citation | International Journal of Hematology, Vol.116 No.1, pp.110-121 | - |
dc.identifier.issn | 0925-5710 | - |
dc.identifier.uri | https://hdl.handle.net/10371/184621 | - |
dc.description.abstract | Optimal treatments for multiple myeloma (MM) patients with high-risk cytogenetics must be determined, but subgroup features are not well-defined. We used real-world data from the Korean Myeloma Registry (KMR) to analyze the characteristics and clinical outcomes of newly diagnosed MM patients with >= 1 high-risk cytogenetic abnormality: Group 1: t(4;14) or t(14;16); Group 2: del(17p); Group 3: t(4;14)/del(17p) or t(14;16)/del(17p). Overall, 347 high-risk patients were identified (males, 48.7%; median age, 63 years). Median progression-free survival (PFS) and overall survival (OS) were 19.0 months (95% CI 17.0-20.0) and 50.0 months (95% CI 37.0-61.0), respectively. PFS (p = 0.047) and OS (p = 0.020) differed significantly between groups. After stratification by transplant eligibility, PFS and OS were significantly poorer in Group 3 among transplant-eligible patients, and even poorer in those with gain(1q). Patients stratified by cytogenetic abnormality and revised International Staging System (R-ISS) had significantly different PFS (p < 0.001) and OS (p = 0.003), with the worst survival in R-ISS III/Group 3 (median OS 21.0 months). Higher number of high-risk cytogenetic abnormalities was a negative prognostic marker for PFS and OS (p < 0.001). Real-world KMR data showed that risk factors for poor prognosis of MM patients included del(17p), R-ISS stage, and number of cytogenetic abnormalities. | - |
dc.language | 영어 | - |
dc.publisher | Japanese Society of Hematology | - |
dc.title | Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805) | - |
dc.title.alternative | x | - |
dc.type | Article | - |
dc.identifier.doi | 10.1007/s12185-022-03332-w | - |
dc.citation.journaltitle | International Journal of Hematology | - |
dc.identifier.wosid | 000793694200002 | - |
dc.identifier.scopusid | 2-s2.0-85131582174 | - |
dc.citation.endpage | 121 | - |
dc.citation.number | 1 | - |
dc.citation.startpage | 110 | - |
dc.citation.volume | 116 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Yoon, Sung-Soo | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.